5
1
semisolid; H NMR (CDCl3, 400 MHz) δ 8.69 (bs, 1H), 8.37 (d, 4.2.10. 3-fluoro-N-(pyridin-2-yl) benzamide (3j) compound 3i
J = 8Hz, 1H), 8.24 (d, J = 4Hz, 1H), 7.83-7.79 (m, 1H), 7.55- was prepared using typical experimental procedure. Cream
7.51 (m, 2H), 7.14-7.11 (m, 1H) ; 13C NMR (CDCl3, 100 MHz) δ
163.9, 151.1, 147.4, 138.8, 136.3, 135.9, 133.0, 131.3, 128.7,
127.1, 120.4, 114.7; IR (CH2Cl2) 2961.4, 2921.5, 2850.3, 1686.9,
1574.9, 1537.5, 1463.5, 1435.5, 1363.6, 1309.6, 1261.7, 1179.1,
1152.9, 1105.0, 1088.2, 1047.7, 1023.4 cm-1 ; ESI-MS (LTQ) :
[M+H]+ 301.15
o
1
powder; m.p 62-64 C; H NMR (CDCl3, 400 MHz) δ 8.90 (bs,
1H), 8.40 (d, J = 8Hz, 1H), 8.27-8.25 (m, 1H), 7.81-7.77 (m,
1H), 7.72-7.66 (m, 2H), 7.51-7.46 (m, 1H), 7.31-7.26 (m, 1H),
7.12-7.08 (m, 1H) ; 13C NMR (CDCl3, 100 MHz) δ 163.5 (1JCF
= 249 Hz) 160.6, 150.3, 146.9, 137.5, 129.5, 121.7, 119.2, 118.4,
113.9, 113.7, 113.3; IR (CH2Cl2) 3391.5, 3007.2, 1524.9, 1434.9,
1274.8, 1261.6, 1046.6 cm-1; ESI-MS (LTQ) : [M+H]+ 231.18
4.2.5. 4-methyl-N-(pyridin-2-yl) benzamide (3e) compound 3e
was prepared using typical experimental procedure. 1H NMR
(CDCl3, 400 MHz) δ 8.81 (bs, 1H), 8.43 (d, J = 8Hz, 1H), 8.29
(d, J = 4Hz, 1H), 7.87 (d, J = 8Hz, 2H), 7.80-7.75 (m, 1H), 7.32
(t, J = 8Hz, 2H), 7.10-7.06 (m, 1H), 2.45 (s, 3H) ; ; 13C NMR
(CDCl3, 100 MHz) δ 165.9, 151.6, 148.1, 142.7, 138.3, 131.5,
130.1, 127.1, 119.9, 114.4, 21.3; IR (CH2Cl2) 2959.6, 2925.1,
2854.8, 1682.6, 1673.9, 1578.8, 1537.0, 1524.8, 1520.2, 1504.7,
1455.6, 1434.7, 1303.2, 1261.9, 1110.5, 1091.7, 1020.1 cm-1 ;
ESI-MS (LTQ) : [M+H]+ 213.10
4.2.11. 4-chloro-N-(pyridin-2-yl) benzamide (3k) compound 3k
was prepared using typical experimental procedure. 1H NMR
(CDCl3, 400 MHz) δ 9.07 (bs, 1H), 8.41 (d, J = 8Hz, 1H), 8.22
(s, 1H), 7.91 (d, J = 8Hz, 2H), 7.80 (t, J = 8Hz, 1H), 7.48 (d, J =
8Hz, 2H), 7.10 (t, J = 8Hz, 1H); 13C NMR (CDCl3, 100 MHz) δ
164.8, 160.6, 151.5, 147.8, 138.6, 132.7, 129.1, 128.8, 120.1,
114.4; IR (CH2Cl2) 3347.4, 2923.7, 2853.6, 1658.7, 1577.2,
1524.5, 1488.6, 1432.2, 1308.4, 1261.5, 1094 cm-1; ESI-MS
(LTQ) : [M+H]+ 233.34
4.2.12. 4-fluoro-N-(pyridin-2-yl) benzamide (3l) compound 3l
was prepared using typical experimental procedure. 1H NMR
(CDCl3, 400 MHz) δ 8.64 (bs, 1H), 8.43 (d, J = 8Hz, 1H), 8.32
(d, J = 4Hz, 1H), 7.89 (d, J = 8Hz, 2H), 7.80-7.76 (m, 1H), 7.37
(d, J = 8Hz, 2H), 7.10-7.07 (m, 1H) ; 13C NMR (CDCl3, 100
MHz) δ 165.6 (1JCF = 249 Hz), 160.6, 152.9, 151.7, 147.9,
138.5, 131.7, 127.3, 127.2, 119.8, 114.1; IR (CH2Cl2) 3369,
2924.1, 2851.5, 1676.9, 1600.7, 1578.5, 1530.2, 1503.9, 1461.7,
1433.3, 1274.8, 1261.5, 1230.7, 1158.4, 1093.1 cm-1; ESI-MS
(LTQ): [M+H]+ 217.23
4.2.6. 4-methoxy-N-(pyridin-2-yl) benzamide (3f) compound 3f
was prepared using typical experimental procedure. 1H NMR
(CDCl3, 400 MHz) δ 8.76 (bs, 1H), 8.42 (d, J = 8Hz, 1H), 8.30
(d, J = 4Hz, 1H), 7.95 (d, J = 12Hz, 2H), 7.79 (t, J= 12Hz, 1H),
7.09-7.06 (m, 1H), 7.01(d, J= 8Hz, 2H) 3.90 (s, 3H) 13C NMR
(CDCl3, 100 MHz) δ 165.2, 162.8, 151.6, 147.9, 138.6, 129.1,
126.4, 119.6, 114.2, 114.0, 55.6; IR (CH2Cl2) 2925.1, 1676.1,
1606.8, 1577.8, 1505.1, 1431.9, 1275.8, 1267.1, 1259.3, 1175.1,
1029.6 cm-1 ; ESI-MS (LTQ) : [M+H]+ 229.12
4.2.7. 2,4-dichloro-N-(pyridin-2-yl)benzamide (3g) compound 3g
was prepared using typical experimental procedure. 1H NMR
(CDCl3, 400 MHz) δ 9.03 (bs, 1H), 8.38 (d, J = 8Hz, 1H), 8.17
(d, J = 4Hz, 1H), 7.81-7.77 (m, 1H), 7.72 (d, J = 8Hz, 1H), 7.50
(d, J = 4Hz, 1H), 7.40-7.37 (m, 1H), 7.11-7.08 (m, 1H); 13C
NMR (CDCl3, 100 MHz) δ 164.0, 162.8, 151.0, 147.9, 138.7,
137.5, 133.3, 131.8, 131.2, 130.3, 127.9, 120.5, 114.3; IR
(CH2Cl2) 3182.9, 2925.3, 1688.6, 1579.4, 1532.6, 1471.6,
1435.6, 1375.2, 1281.7, 1239.0, 1150.1, 1096.7, 1050.4 cm-1;
ESI-MS (LTQ) : [M+H]+ 267.18
4.2.13.
3,5-bis(benzyloxy)-N-(pyridin-2-yl)benzamide
(3m)
compound 3m was prepared using typical experimental
procedure. Yellow semisolid; 1H NMR (CDCl3, 400 MHz) δ 9.10
(bs, 1H), 8.43 (d, J = 8Hz, 1H), 8.23-8.22 (m, 1H), 7.79-7.74 (m,
1H), 7.46-7.34 (m, 10H), 7.19 (d, J = 4Hz, 2H), 7.08-7.05 (m,
1H); 6.82 (t, J = 4Hz, 1H); 5.08 (s, 4H); 13C NMR (CDCl3, 100
MHz) δ 165.7, 160.1, 151.6, 147.9, 138.5, 136.5, 136.4, 128.7,
128.2, 127.6, 119.9, 114.3, 106.4, 106.1, 70.3; IR (CH2Cl2)
3007.1, 2872, 1678.5, 1593.6, 1520.3, 1433.6, 1275.1, 1261.6,
1158.7, 1054.7 cm-1; ESI-MS (LTQ) : [M+H]+ 411.41
4.2.8. 3-acetamido-N-(pyridin-2-yl) benzamide (3h) compound
4.2.14.
4-(benzyloxy)-N-(pyridin-2-yl)benzamide
(3n)
3g was prepared using typical experimental procedure. Brown
compound 3n was prepared using typical experimental
procedure. White semisolid; H NMR (CDCl3, 400 MHz) δ 8.55
1
1
semisolid; H NMR (CDCl3 + MeOD), 400 MHz) δ 9.22 (bs,
1H), 8.69 (s, 1H), 8.33 (d, J = 8Hz, 1H), 8.19 (s, 1H), 7.99 (s,
1H), 7.89 (d, J = 8Hz, 1H), 7.74 (t, J = 8Hz, 1H), 7.59 (d, J =
8Hz, 1H); 7.37 (t, J = 8Hz, 1H), 7.04 (t, J = 4Hz, 1H), 2.14 (s,
3H); 13C NMR (CDCl3 + MeOD), 100 MHz) δ 175.3, 169.2,
165.9, 158.4, 151.6, 138.9, 138.4, 134.8, 129.4, 123.7, 122.7,
119.9, 118.8, 114.5; 24.3; IR (CH2Cl2) 3304.9, 3007.2, 2922.0,
1670, 1592.8, 1526, 1486.7, 1433.4, 1372.3, 1274.6, 1261.8 cm-
1; ESI-MS (LTQ) : [M+H]+ 256.35
(bs, 1H), 8.41 (d, J = 8Hz, 1H), 8.32 (d, J = 4Hz, 1H), 7.93 (d, J
= 8Hz, 2H), 7.79 (t, J = 8Hz, 1H), 7.48-7.37 (m, 5H), 7.10 (d, J =
8Hz, 3H), 5.17 (s, 2H); 13C NMR (CDCl3, 100 MHz) δ 165.0,
162.1, 151.7, 147.9, 138.4, 136.3, 129.1, 128.7, 128.1, 127.4,
126.7, 119.8, 115.0, 114.1, 69.9; IR (CH2Cl2) 3393.2, 2958.5,
2925.6, 2860.1, 1736.7, 1679.3, 1601.4, 1507, 1432.9, 1298,
1261.0, 1024.4 cm-1;
4.2.15. 4-cyclohexyl-N-(pyridin-2-yl)benzamide (3o) compound
3o was prepared using typical experimental procedure. cream
4.2.9. 3-chloro-N-(pyridin-2-yl) benzamide (3i) compound 3i was
prepared using typical experimental procedure. White powder;
m.p 95-97 oC; 1H NMR (CDCl3, 400 MHz) δ 8.64 (bs, 1H), 8.40
(d, J = 12Hz, 1H), 8.33 (d, J = 4Hz, 1H), 7.96 (s, 1H), 7.82 (t, J
= 8Hz, 2H), 7.58 (d, J = 8Hz, 1H), 7.49 (t, J = 8Hz, 1H), 7.14 (t,
J = 8Hz, 1H) ; 13C NMR (CDCl3, 100 MHz) δ 164.3, 151.3,
148.1, 138.5, 135.9, 135.3, 132.5, 130.3, 127.9, 125.1, 120.3,
114.1; IR (CH2Cl2) 3373.0, 3016.6, 2931.0, 2854, 1678.3,
1576.5, 1526, 1433.5, 1307.3, 1261.1, 1048.7 cm-1; ESI-MS
(LTQ) : [M+H]+ 231.18
1
semisolid; H NMR (CDCl3, 400 MHz) δ 8.94 (bs, 1H), 8.31 (d,
J = 8Hz, 1H), 8.13 (s, 1H), 7.90-7.86 (m, 2H), 7.70 (t, J = 8Hz,
1H), 7.10 (t, J = 8Hz, 2H), 7.00-6.97 (m, 1H), 1.18 (s, 11H); 13C
NMR (CDCl3, 100 MHz) δ 166.4, 164.8, 163.9, 151.6, 147.8,
138.6, 130.5, 129.8, 120.0, 116.0, 115.8, 114.3, 31.9, 29.9, 22.7,
14.1 IR (CH2Cl2) 3013.4, 2924.5, 2855.8, 1679.82, 1574, 1432.8,
1304.3, 1274.9, 1261.5, 1028.2 cm-1; ESI-MS (LTQ) : [M+H]+
281.41
4.2.16. 2-bromo-N-(pyridin-2-yl)benzamide (3p) compound 3p
was prepared using typical experimental procedure. Brown